- Details
- Description
-
Packaging Size1c/bottle
-
Strength4mg
-
CompositonIxazomib
-
TreatmentMultiple Myeloma(MM)
-
FormCapsule
-
BrandISADX
-
Quantity Unit4mg*3c/bottle/Box
-
ManufacturerBIGBEAR Pharma,Laos PDR
Ixazomib is an oral proteasome inhibitor used in the treatment of multiple myeloma. Ixazomib is the first oral second-generation proteasome inhibitor that was approved by the FDA.
Multiple Myeloma
Indicated in patients who have received at least 1 prior therapy
Use in combination with lenalidomide and dexamethasone
Continue treatment until disease progression or unacceptable toxicity
Starting doses
- Ixazomib: 4 mg PO on days 1, 8, and 15 of a 28-day cycle; take 1 hr ac or 2 hr pc
- Lenalidomide: 25 mg PO on days 1-21 of a 28-day cycle; take with or without food
- Dexamethasone: 40 mg PO in morning on days 1, 8, 15, and 22 of a 28-day cycle
Dose reductions
-
For starting dose of 4 mg
- First reduction: 3 mg
- Second reduction: 2.3 mg
- Unable to tolerate 2.3-mg dose: Discontinue therapy
